EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ASAS recommendations on reporting axial spondyloarthritis clinical trials

Floris A van Gaalen, Victoria Navarro-Compán, Xenofon Baraliakos, Filip van den Bosch, Lianne S Gensler, Ihsane Hmamouchi, Robert Landewé, Pedro M Machado, Helena Marzo-Ortega, Valeria Rios Rodriguez, Denis Poddubnyy, Sofia Ramiro und 1 weitere

Annals of the Rheumatic Diseases · 2025

DOI: 10.1016/j.ard.2025.07.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Floris A van Gaalen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: f.a.van_gaalen@lumc.nl. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Axial Spondyloarthritis, Research Design, Outcome Assessment, Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS). METHODS: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented. (2) The SG proposal was presented, discussed, and modified in WG meetings. (3) WG proposal was discussed and voted on by ASAS members during the 2024 annual ASAS workshop. RESULTS: Forty-two baseline features relevant for all axSpA clinical trials and 8 additional features for disease-modifying drug trials were defined including descriptions on how to report them. Additionally, recommendations on how to report 20 trial outcomes at baseline and follow-up timepoints were put forward. Finally, recommendations on how to report 11 outcomes of instruments additionally endorsed by ASAS but not in the COS were formulated. Proposals for baseline features, COS outcomes, and outcomes not in COS were approved by ASAS members (with 84%, 85%, and 93% of members in favour, respectively). CONCLUSIONS: These ASAS-endorsed recommendations on axSpA clinical trial reporting provide a standardised approach to reporting both baseline features as well as outcomes from axSpA clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicAxial SpondyloarthritisResearch DesignOutcome Assessment, Health CareSpondylarthritisHumansAntirheumatic AgentsSocieties, Medical

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: f.a.van_gaalen@lumc.nl.
  • Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain.
  • Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany.
  • VIB-UGent Center for Inflammation Research, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Ghent University Hospital, Department of Rheumatology, Ghent, Belgium.
  • Department of Medicine, Division of Rheumatology, University of California, San Francisco, California, USA.
  • Faculty of Medicine, Health Sciences Research Center (CReSS), International University of Rabat (UIR), Rabat, Morocco.

Förderung

  • National Institute for Health and Care Research
  • UCLH Biomedical Research Centre
  • University College London Hospitals NHS Foundation Trust
  • National Health Service Corps
  • Leeds Biomedical Research Centre

Zitieren

APA

van Gaalen, F. A., Navarro-Compán, V., Baraliakos, X., van den Bosch, F., Gensler, L. S., Hmamouchi, I., Landewé, R., Machado, P. M., Marzo-Ortega, H., Rodriguez, V. R., Poddubnyy, D., Ramiro, S., & van der Heijde, D. (2025). ASAS recommendations on reporting axial spondyloarthritis clinical trials. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.07.017

Vancouver

van Gaalen FA, Navarro-Compán V, Baraliakos X, van den Bosch F, Gensler LS, Hmamouchi I, et al. ASAS recommendations on reporting axial spondyloarthritis clinical trials. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.07.017

BibTeX
@article{vanGaalen2025,
  author = {van Gaalen, Floris A and Navarro-Compán, Victoria and Baraliakos, Xenofon and van den Bosch, Filip and Gensler, Lianne S and Hmamouchi, Ihsane and Landewé, Robert and Machado, Pedro M and Marzo-Ortega, Helena and Rodriguez, Valeria Rios and Poddubnyy, Denis and Ramiro, Sofia and van der Heijde, Désirée},
  title = {ASAS recommendations on reporting axial spondyloarthritis clinical trials},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  doi = {10.1016/j.ard.2025.07.017}
}
Kostenlos starten →